Special Edition: Medications in the Pipeline for Cardiometabolic Disease

About this episode

Neil Skolnik interviews Dr. Juan Frias about the latest cardiometabolic medications and their characteristics.

In this special edition of DOC Updates , Neil Skolnik speaks with Dr. Juan Frias, who catalogues the latest cardiometabolic medications, emphasizing the distinguishing characteristics of each. This special episode is sponsored with support from Lilly . Presented by: Neil Skolnik , MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Juan Pablo Frias , MD, Medical Director and Principal Investigator, Los Angeles Institute for Metabolic Research, Adjunct Professor of Medicine at Charles Drew University of Medicine and Science

People in this episode

Host: Neil Skolnik

Guest: Dr. Juan Frias

Topics covered

• cardiometabolic disease
• medications
• healthcare
• diabetes
• medical research

Keywords

• cardiometabolic medications
• diabetes
• healthcare
• medical research
• Lilly

Sponsors

Lilly

Mentioned in this episode

Organizations: American Diabetes Association, Los Angeles Institute for Metabolic Research, Charles Drew University of Medicine and Science, Abington Jefferson Health

Places: Thomas Jefferson University

More episodes of DOC Updates

• Special Edition: Hypertension Part 2—Advanced Hypertension Management: Uncontrolled and Resistant Hypertension and the Importance of Aldosterone · September 8, 2026 · 40 min
• Special Edition: Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH) · September 3, 2026 · 23 min
• Special Edition: Evidence-Based Strategies for Weight Loss and Long-Term Weight Maintenance · August 24, 2026 · 32 min
• Special Edition: What's Next—The Role of Health Systems in Managing CKD Associated with T1D & T2D · August 17, 2026 · 33 min
• Katherine Tuttle on SGLT2s & CKD in T2D, Alexander Turchin on medications after Metformin, and High vs. Low CVD Risk, the ADA's statement on employment and diabetes, and more! · August 10, 2026 · 36 min
• Impact of Finerenone on Albuminuria in T1D, National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs, and more! · August 10, 2026 · 32 min